Embracing Future Holdings Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • 8YY

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.02
  • (As of Thursday Closing)

Embracing Future Holdings General Information

Description

Embracing Future Holdings Ltd formerly, Biolidics Ltd is engaged in technology development, technology transfer, marketing, sales, and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are: Cancer, Infectious Diseases, E-sports, and Corporate. The company generates the majority of its revenue from the E-sports segment, which involves identifying and assessing potential collaboration partners, technology, digital platforms, products, and services related to E-Sports.. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and other countries.

Contact Information

Formerly Known As
Clearbridge BioMedics, Biolidics
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 37 Jalan Pemimpin
  • Number 02-07
  • Mapex, 577177
  • Singapore
+65 9662
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Stock Exchange
SES
Corporate Office
  • 37 Jalan Pemimpin
  • Number 02-07
  • Mapex, 577177
  • Singapore
+65 9662

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Embracing Future Holdings Stock Performance

As of 17-Jul-2025, Embracing Future Holdings’s stock price is $0.02. Its current market cap is $30.3M with 1.69B shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $30.3M 1.69B 1.32M

Embracing Future Holdings Financials Summary

As of 31-Dec-2024, Embracing Future Holdings has a trailing 12-month revenue of $587K.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 37,834 37,834 7,039 10,741
Revenue 587 587 206 1,805
EBITDA (2,266) (2,266) (900) (6,163)
Net Income (2,570) (2,570) (1,852) (6,798)
Total Assets 3,434 3,434 516 4,540
Total Debt 1,287 1,287 1,532 2,247
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Embracing Future Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Embracing Future Holdings‘s full profile, request access.

Request a free trial

Embracing Future Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Embracing Future Holdings Ltd formerly, Biolidics Ltd is engaged in technology development, technology transfer, marketi
Biotechnology
Mapex, Singapore
7 As of 2024

San Francisco, CA
 

Bengaluru, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Embracing Future Holdings Competitors (10)

One of Embracing Future Holdings’s 10 competitors is Standard BioTools, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Standard BioTools Formerly VC-backed San Francisco, CA
Biocon Formerly PE-Backed Bengaluru, India
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India
Merck & Co. Corporation Rahway, NJ
Glenmark Pharmaceuticals Corporation Mumbai, India
You’re viewing 5 of 10 competitors. Get the full list »

Embracing Future Holdings Patents

Embracing Future Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2019515678-A System and method for enriching target cells in a sample Active 04-May-2016
AU-2016405636-A1 Systems and methods for enriching target cells in a sample Active 04-May-2016
AU-2016405636-B2 Systems and methods for enriching target cells in a sample Active 04-May-2016
EP-3455337-A1 Systems and methods for enriching target cells in a sample Inactive 04-May-2016
EP-3455337-A4 Systems and methods for enriching target cells in a sample Inactive 04-May-2016 B01L3/502761
To view Embracing Future Holdings’s complete patent history, request access »

Embracing Future Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Embracing Future Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Embracing Future Holdings‘s full profile, request access.

Request a free trial

Embracing Future Holdings Acquisitions (1)

Embracing Future Holdings’s most recent deal was a Merger/Acquisition with Biomedics Laboratory for . The deal was made on 26-May-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biomedics Laboratory 26-May-2020 Merger/Acquisition Laboratory Services (Healthcare)
To view Embracing Future Holdings’s complete acquisitions history, request access »

Embracing Future Holdings ESG

Risk Overview

Risk Rating

Updated August, 24, 2023

30.86 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Healthcare

Industry

of 587

Rank

Percentile

Medical Devices

Subindustry

of 198

Rank

Percentile

To view Embracing Future Holdings’s complete esg history, request access »

Embracing Future Holdings FAQs

  • When was Embracing Future Holdings founded?

    Embracing Future Holdings was founded in 2009.

  • Where is Embracing Future Holdings headquartered?

    Embracing Future Holdings is headquartered in Mapex, Singapore.

  • What is the size of Embracing Future Holdings?

    Embracing Future Holdings has 7 total employees.

  • What industry is Embracing Future Holdings in?

    Embracing Future Holdings’s primary industry is Biotechnology.

  • Is Embracing Future Holdings a private or public company?

    Embracing Future Holdings is a Public company.

  • What is Embracing Future Holdings’s stock symbol?

    The ticker symbol for Embracing Future Holdings is 8YY.

  • What is the current stock price of Embracing Future Holdings?

    As of 17-Jul-2025 the stock price of Embracing Future Holdings is $0.02.

  • What is the current market cap of Embracing Future Holdings?

    The current market capitalization of Embracing Future Holdings is $30.3M.

  • What is Embracing Future Holdings’s current revenue?

    The trailing twelve month revenue for Embracing Future Holdings is $587K.

  • Who are Embracing Future Holdings’s competitors?

    Standard BioTools, Biocon, Intas Pharmaceuticals, Merck & Co., and Glenmark Pharmaceuticals are some of the 10 competitors of Embracing Future Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »